EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunohistochemical Changes in MMR Status, ER/PR, and p53 Expression in Recurrent Endometrial Carcinomas

Zeliha Guzeloz iD, Ozce Kutlu, Ozgur Erdogan iD, Gonul Demir, Bugra Taygun Gulle, Muzaffer Sancı, Mihriban Erdogan iD, Canan Kelten Talu

Medicina · 27.04.2026 · 62 (5) · 828

DOI: 10.3390/medicina62050828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, online erschienen am 27.04.2026. Verfasst von Zeliha Guzeloz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, İzmir City Hospital, Izmir 35540, Türkiye. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Tumor Suppressor Protein p53, Receptors, Progesterone, Receptors, Estrogen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moltec Health Services Production and Marketing Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: The aim of this study is to assess the mismatch repair (MMR) status and immunohistochemical changes in cases of recurrent endometrial cancer following primary surgery and to evaluate the impact of these changes on prognosis. Materials and Methods: Thirty-one patients diagnosed with endometrial cancer who underwent surgery and had pathologically confirmed recurrences were evaluated. Changes in MMR protein expression, estrogen receptor (ER)/progesterone receptor (PR), and p53 expression in primary surgery and recurrent tumor tissues were assessed using immunohistochemical methods. Prognostic factors influencing these parameters and survival data were investigated.

Results

In the assessment of recurrent materials, there were four cases where the MLH-1&PMS-2 staining status changed from intact to loss and four cases that changed from loss to intact. No changes were observed in regard to MSH-2 &MSH-6 staining. The ratios of pMMR and dMMR following the primary surgery were 55% (n = 17) and 45% (n = 14), respectively. Four cases transitioned from pMMR to dMMR, and four cases transitioned from dMMR to pMMR. After recurrence, changes in the ER, PR, and P53 status were observed in seven, three, and three patients, respectively.

Conclusions

Changes in the MMR status, receptors, and P53 were observed. It is necessary to re-evaluate prognostic parameters via biopsies in recurring cases and to adjust rescue treatments accordingly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsTumor Suppressor Protein p53Receptors, ProgesteroneReceptors, EstrogenDNA Mismatch RepairNeoplasm Recurrence, LocalHumansFemaleImmunohistochemistryMiddle AgedAgedPrognosisAdultAged, 80 and over

Stichwörter der Autor:innen

ER/PRendometrial cancermismatch repairp53recurrence

Substanzen

Tumor Suppressor Protein p53Receptors, ProgesteroneReceptors, EstrogenTP53 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, İzmir City Hospital, Izmir 35540, Türkiye.
  • Department of Pathology, Tepecik Training and Research Hospital, Izmir 35020, Türkiye.
  • Department of Gynecologic Oncology, İzmir City Hospital, Izmir 35540, Türkiye.
  • Public Health Department, Provincial Health Directorate, Izmir 35250, Türkiye.
  • Department of Gynecologic Oncology, Izmir Faculty of Medicine, University of Health Science Türkiye, Izmir 35100, Türkiye.
  • Department of Radiation Oncology, Izmir Faculty of Medicine, University of Health Science Türkiye, Izmir 35100, Türkiye.

ORCID-Profile: Zeliha Guzeloz, Ozgur Erdogan, Mihriban Erdogan

Förderung

  • Moltec Health Services Production and Marketing Company

Zitieren

APA

Guzeloz, Z., Kutlu, O., Erdogan, O., Demir, G., Gulle, B. T., Sancı, M., Erdogan, M., & Talu, C. K. (2026). Immunohistochemical Changes in MMR Status, ER/PR, and p53 Expression in Recurrent Endometrial Carcinomas. Medicina, 62(5), 828. https://doi.org/10.3390/medicina62050828

Vancouver

Guzeloz Z, Kutlu O, Erdogan O, Demir G, Gulle BT, Sancı M, et al. Immunohistochemical Changes in MMR Status, ER/PR, and p53 Expression in Recurrent Endometrial Carcinomas. Medicina. 2026;62(5):828. doi:10.3390/medicina62050828

BibTeX
@article{Guzeloz2026,
  author = {Guzeloz, Zeliha and Kutlu, Ozce and Erdogan, Ozgur and Demir, Gonul and Gulle, Bugra Taygun and Sancı, Muzaffer and Erdogan, Mihriban and Talu, Canan Kelten},
  title = {Immunohistochemical Changes in MMR Status, ER/PR, and p53 Expression in Recurrent Endometrial Carcinomas},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {5},
  pages = {828},
  doi = {10.3390/medicina62050828}
}
Kostenlos starten →